Revenue by quarter
US$ · last 8| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $481.0M | $229.9M | 1.90 |
| Q1 FY2026 | $376.7M | $150.0M | 1.22 |
| Q4 FY2025 | $451.8M | -$141.6M | -1.20 |
| Q3 FY2025 | $354.3M | $175.2M | 1.43 |
Newest filings
All 542| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 8-K | 30 Sep 2026 | 30 Sep, 4:20 PM | |
| 8-K | 22 Sep 2026 | ||
| 8-K | 18 Sep 2026 | ||
| 8-K | 16 Sep 2026 | ||
| 8-K | 18 Aug 2026 | ||
| 10-Q | 6 Aug 2026 | ||
| 8-K | 6 Aug 2026 | ||
| 8-K | 2 Jul 2026 |
Description
- Ticker
- HALO-US
- Exchange
- Nasdaq
- Index
- S&P MidCap 400
- Industry
- Biological Products, (No Diagnostic Substances)
- SIC division
- Manufacturing
- CIK
- 0001159036
- LEI
- 529900242I3SV9AGM753
- FIGI
- BBG000CZ8W54
- Share class FIGI
- BBG001SGX585
- Fiscal year ends
- Dec
- Filings held
- 542 since 2001
- 8-K events
- 285
- Shares short
- 15.3M, 30 Sep 2026
Financial statements
The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.
| Fiscal period | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Filed | 12 Mar 2012 | 1 Mar 2013 | 28 Feb 2014 | 2 Mar 2015 | 29 Feb 2016 | 28 Feb 2017 | 20 Feb 2018 | 21 Feb 2019 | 24 Feb 2020 | 23 Feb 2021 | 22 Feb 2022 | 21 Feb 2023 | 20 Feb 2024 | 18 Feb 2025 | 17 Feb 2026 | 17 Feb 2026 | 17 Feb 2026 |
| +Total revenues | 14M | 14M | 56M | 42Mr | 55Mr | 75M | 135M | 147M | 317M | 152M | 196M | 268M | 443M | 660M | 829M | 1,015M | 1,397M |
| +Cost of sales | – | – | – | – | – | – | – | – | 31M | 10M | 46M | 43M | 81M | 139M | 192M | 159M | 229M |
| +Amortization of intangibles | – | – | – | – | – | – | – | – | – | – | – | 0M | 0M | 43M | 74M | 71M | 77M |
| +Research and development | 57M | 52M | 58M | 70Mr | 97Mr | 80M | 93M | 151M | 151M | 150M | 141M | 34M | 36M | 67M | 76M | 79M | 82M |
| +Selling, general and administrative | 15M | 15M | 18M | 25Mr | 32Mr | 36M | 40M | 46M | 54M | 61M | 77M | 46M | 50M | 144M | 149M | 154M | 207M |
| +Impairment of intangible asset | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0M | 0M | 49M |
| +Acquired in-process research and development expense | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0M | 0M | 285M |
| −Total operating expenses | 72M | 68M | 76M | 96Mr | 135M | 138M | 163M | 230M | 236M | 221M | 264M | 123M | 167M | 393M | 492M | 464M | 928M |
| Operating income | -59M | -54M | -20M | -54Mr | -80Mr | -63M | -28M | -83M | 81M | -69M | -68M | 144M | 276M | 268M | 338M | 552M | 469M |
| % of total revenues | -427.6% | -398.2% | -35.4% | -126.7% | -146.8% | -83.7% | -20.3% | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| +Investment and other income, net | 0.1M | 1M | 0.1M | 0.1M | 0.2Mr | 0.2M | 0.4M | 1.3M | 2.6M | 7.6M | 7M | 5.4M | 1.1M | 1M | 16M | 24M | 22M |
| −Inducement expense related to convertible notes | – | – | – | – | – | – | – | – | – | – | 0M | 0M | 21M | 2.7M | 0M | 0M | 5.5M |
| +Contingent liability fair value measurement gain | – | – | – | – | – | – | – | – | – | – | – | – | 0M | 0M | 13M | 0M | 0M |
| −Interest expense | – | – | 0M | 0M | 3.3Mr | 5.6M | 5.2M | 20M | 22M | 18M | 12M | 20M | 7.5M | 17M | 19M | 18M | 18M |
| Income before income tax expense | – | – | – | – | – | -68M | -32M | -102M | 62M | -80M | -72M | 129M | 249M | 249M | 348M | 557M | 467M |
| % of total revenues | -90.8% | -23.9% | -69.4% | 19.5% | -52.5% | -36.9% | 48.3% | 56.1% | 37.7% | 42.0% | 54.9% | 33.4% | |||||
| −Income tax expense | – | – | – | – | – | 0M | 0M | 1.2M | -1.4M | 0.5M | -0M | 0.2M | -154M | 47M | 67M | 113M | 150M |
| Net income | -58M | -53M | -20M | -54M | -84Mr | -68M | -32M | -103M | 63M | -80M | -72M | 129M | 403M | 202M | 282M | 444M | 317M |
| % of total revenues | -426.9% | -390.8% | -35.2% | -126.5% | -152.3% | -90.8% | -23.9% | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Earnings Per Share, Basic and Diluted | -0.67 | -0.56 | -0.19 | -0.48 | -0.74 | -0.56 | -0.25 | -0.81 | – | -0.56 | -0.50 | – | – | – | – | – | – |
| Basic | – | – | – | – | – | – | -0.25 | -0.81 | 0.46 | -0.56 | -0.50 | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 | 2.64 |
| Diluted | – | – | – | – | – | – | -0.25 | -0.81 | 0.45 | -0.56 | -0.50 | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 | 2.56 |
| Weighted Average Number of Shares Outstanding, Basic and Diluted | – | – | 103M | 111M | 113Mr | 123M | 127M | 128M | – | 144M | 144M | – | – | – | – | – | – |
| Basic | – | – | – | – | – | – | 127M | 128M | 136M | 144M | 144M | 136M | 141M | 137M | 132M | 127M | 120M |
| Diluted | – | – | – | – | – | – | 127M | 128M | 139M | 144M | 144M | 142M | 147M | 141M | 134M | 129M | 124M |
Hover a figure for its source.r restated in a later filing– not reported in that period
Lines in the order and wording of the 10-K filed 17 Feb 2026. 234 of 234 subtotals add up to the company's own totals, and the balance sheet balances in 77 of 77 periods. Newest filing read: 6 Aug 2026.
Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.
Charts
Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.
Revenue · quarterly · US$
Latest Jun 2026: $481M
Revenue = rev
Method. Each month-end, the trailing-twelve-month diluted EPS known that month (from filings filed by then) at the 10th, 50th and 90th percentile of this stock's own month-end P/E from 2019-05 to 2026-10. Months with the figure at or below zero are left out. A summary of the multiples the stock has traded at, not a value.
Ratios
Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.
| Fiscal year ending | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on common equity | – | – | −126.5% | −179.2% | n/m | n/m | −76.4% | n/m | n/m | −35.1% | −42.4% | 106.3% | 231.4% | 110.2% | 222.1% | 198.4% | 153.6% |
| Return on assets | – | – | −25.2% | −53.4% | −70.6% | −51.1% | −18.5% | −46.5% | 16.1% | −16.7% | −14.4% | 22.5% | 47.8% | 13.7% | 15.8% | 23.4% | 13.8% |
| Return on capital | – | – | −100.3% | −94.8% | −117.3% | −104.2% | −33.9% | −55.3% | 25.6% | −17.7% | −17.8% | 28.2% | 26.9% | 15.8% | 16.7% | 25.5% | 15.7% |
| Return on invested capital | – | – | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 123.2% | 85.0% | 26.4% | 19.6% | 27.3% | 16.7% |
| Gross margin | 97.7% | 92.8% | 99.5% | 97.4% | 88.6% | 69.8% | 78.3% | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% |
| EBITDA margin | −417.0% | −387.2% | −33.4% | −124.1% | −144.5% | −81.3% | −19.1% | −55.1% | 26.3% | −44.1% | −32.4% | 55.1% | 62.9% | 41.5% | 42.0% | 55.3% | 34.4% |
| Operating margin | −427.6% | −398.2% | −35.4% | −126.7% | −146.8% | −83.7% | −20.3% | −56.7% | 25.6% | −45.7% | −34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Incremental operating margin | – | −8901.5% | 81.1% | 245.5% | −214.9% | 84.7% | 59.6% | −479.3% | 96.6% | 91.2% | 3.9% | 295.9% | 74.9% | −3.9% | 41.4% | 115.0% | −21.6% |
| Pretax margin | – | – | – | – | – | −90.8% | −23.9% | −69.4% | 19.5% | −52.5% | −36.9% | 48.3% | 56.1% | 37.7% | 42.0% | 54.9% | 33.4% |
| Profit margin | −426.9% | −390.8% | −35.2% | −126.5% | −152.3% | −90.8% | −23.9% | −70.2% | 19.9% | −52.9% | −36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Net income to common margin | −426.9% | −390.8% | −35.2% | −126.5% | −152.3% | −90.8% | −23.9% | −70.2% | 19.9% | −52.9% | −36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Effective tax rate | – | – | – | – | – | n/m | n/m | n/m | −2.2% | n/m | n/m | 0.2% | −62.0% | 18.8% | 19.2% | 20.3% | 32.1% |
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
Key points
Revenue rose 48% to $481.0 million
Total revenue was $481.0 million, up from $325.7 million a year earlier. The increase was primarily driven by royalty revenue growth and higher product sales.
Royalties drove most of the growth
Royalty revenue was $307.7 million, up 50% from $205.6 million, and made up most of total revenue for the quarter.
Operating and net income increased
Operating income was $287.7 million, against $202.4 million. GAAP diluted EPS was $1.90, against $1.33 a year earlier.
Non-GAAP EPS and adjusted EBITDA rose
Adjusted EBITDA was $328.8 million, against $225.5 million. Non-GAAP diluted EPS was $2.28, against $1.54.
Product sales increased year over year
Product sales, net were $129.6 million, against $81.5 million, and contributed to the 48% increase in total revenue.
Partner product launches drove royalties
Royalty growth was attributed to continued uptake of partner products launched since 2020, predominantly VYVGART Hytrulo by argenx and DARZALEX SC by Janssen, plus other recent launches.
Collaboration revenue rose
Revenues under collaborative agreements were $43.7 million, against $38.6 million in the second quarter of 2025.
Cost of sales rose with bulk sales
Cost of sales was $79.2 million, against $46.4 million, primarily due to higher bulk rHuPH20 sales.
Acquisitions lifted amortization and R&D
Amortization of intangibles was $29.5 million, against $17.8 million, from the Elektrofi acquisition. R&D was $27.7 million, against $17.5 million, mainly from Elektrofi and Surf Bio.
SG&A rose on consulting and litigation
SG&A was $57.0 million, against $41.6 million, mainly from consulting and professional fees, litigation costs, the Elektrofi and Surf Bio acquisitions, and higher compensation.
Total revenue guidance raised
Full-year total revenue is now expected at $1.835 billion to $1.910 billion, up from $1.710 billion to $1.810 billion.
Royalty revenue guidance raised
Full-year royalty revenue is now expected at $1.220 billion to $1.245 billion, up from $1.130 billion to $1.170 billion.
Adjusted EBITDA guidance raised
Adjusted EBITDA is now expected at $1.225 billion to $1.280 billion, up from $1.125 billion to $1.205 billion, including about $60 million of Hypercon and Surf Bio investment.
Non-GAAP EPS guidance raised
Non-GAAP diluted EPS is now expected at $8.65 to $9.00, up from $7.75 to $8.25. The range does not include potential future share repurchases.
Guidance
- Total revenue$1.835 billion to $1.910 billionfull year 2026 · raised from $1.710 billion to $1.810 billion
- Royalty revenue$1.220 billion to $1.245 billionfull year 2026 · raised from $1.130 billion to $1.170 billion
- Adjusted EBITDA$1.225 billion to $1.280 billionfull year 2026 · raised from $1.125 billion to $1.205 billion
- Non-GAAP diluted EPS$8.65 to $9.00full year 2026 · raised from $7.75 to $8.25
- Hypercon and Surf Bio investmentapproximately $60 millionfull year 2026 · kept from approximately $60 million
- Share repurchasesat least $400 million2026 · kept from at least $400 million
In their words
“Based on these record results, we are raising our full year 2026 financial guidance.” Dr. Helen Torley, President and Chief Executive Officer
“Overall, these results illustrate our continued ability to create multiple waves of revenue opportunities that will drive long-term shareholder value” Dr. Helen Torley, President and Chief Executive Officer
“We have also demonstrated our commitment to returning significant capital to shareholders, repurchasing $333 million of shares in 2Q 2026, at an average price of $69.30.” Dr. Helen Torley, President and Chief Executive Officer
Coming up
Quarterly update call on results day. Management hosted a quarterly update conference call for the second quarter on August 6, 2026, at 1:30 p.m. PT.
Incyte may nominate more targets. Incyte holds an option to nominate up to two additional targets for use with ENHANZE under the July 2026 collaboration.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
This company reports no segment split in its annual report.
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 30 Sep 2026 | 30 Sep, 4:20 PM ET | 8-K | Leadership change | 5.02 | |
| 22 Sep 2026 | 8-K | Material agreementNew debtShare sale | 1.01, 2.03, 3.02, 9.01 | ||
| 18 Sep 2026 | 8-K | Other events | 8.01, 9.01 | ||
| 16 Sep 2026 | 8-K | Other events | 8.01, 9.01 | ||
| 18 Aug 2026 | 8-K | Leadership change | 5.02 | ||
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 | ||
| 2 Jul 2026 | 8-K | Leadership change | 5.02 | ||
| 11 May 2026 | 8-K | Results | 2.02, 9.01 | ||
| 7 May 2026 | 8-K | Shareholder vote | 5.07 | ||
| 30 Apr 2026 | 8-K | Leadership change | 5.02, 9.01 | ||
| 24 Apr 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 | ||
| 12 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 | ||
| 17 Feb 2026 | 8-K | Results | 2.02, 9.01 | ||
| 28 Jan 2026 | 8-K | Results | 2.02, 9.01 | ||
| 9 Dec 2025 | 8-K | Leadership change | 5.02 | ||
| 8 Dec 2025 | 8-K | Leadership change | 5.02 | ||
| 24 Nov 2025 | 8-K | Leadership change | 5.02 | ||
| 12 Nov 2025 | 8-K | Material agreementNew debtShare sale | 1.01, 2.03, 3.02, 9.01 | ||
| 7 Nov 2025 | 8-K | Other events | 8.01, 9.01 | ||
| 5 Nov 2025 | 8-K | Material agreementNew debtOther events | 1.01, 2.03, 8.01, 9.01 | ||
| 3 Nov 2025 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | ||
| 14 Oct 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 6 Oct 2025 | 8-K | Leadership change | 5.02 | ||
| 3 Oct 2025 | 8-K | Material agreement | 1.01, 9.01 | ||
| 1 Oct 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 5 Aug 2025 | 8-K | Results | 2.02, 9.01 | ||
| 6 May 2025 | 8-K | Results | 2.02, 9.01 | ||
| 2 May 2025 | 8-K | Shareholder vote | 5.07 | ||
| 21 Mar 2025 | 8-K | Leadership change | 5.02 | ||
| 18 Feb 2025 | 8-K | Results | 2.02, 9.01 | ||
| 13 Feb 2025 | 8-K | Leadership change | 5.02 | ||
| 8 Jan 2025 | 8-K | Results | 2.02, 9.01 | ||
| 31 Oct 2024 | 8-K | Results | 2.02, 9.01 | ||
| 6 Aug 2024 | 8-K | Results | 2.02, 9.01 | ||
| 7 May 2024 | 8-K | Results | 2.02, 9.01 | ||
| 26 Apr 2024 | 8-K | Shareholder vote | 5.07, 9.01 | ||
| 20 Feb 2024 | 8-K | Results | 2.02, 9.01 | ||
| 17 Jan 2024 | 8-K | Results | 2.02 | ||
| 6 Nov 2023 | 8-K | Results | 2.02, 9.01 | ||
| 7 Sep 2023 | 8-K | Other events | 8.01 | ||
| 8 Aug 2023 | 8-K | Results | 2.02, 9.01 | ||
| 9 May 2023 | 8-K | Results | 2.02, 9.01 | ||
| 8 May 2023 | 8-K | Shareholder vote | 5.07 | ||
| 16 Mar 2023 | 8-K | Investor update | 7.01, 9.01 | ||
| 13 Mar 2023 | 8-K | Other events | 8.01 | ||
| 23 Feb 2023 | 8-K | Leadership change | 5.02 | ||
| 21 Feb 2023 | 8-K | Results | 2.02, 9.01 | ||
| 6 Feb 2023 | 8-K | Leadership change | 5.02 | ||
| 10 Jan 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 8 Nov 2022 | 8-K | Results | 2.02, 9.01 |
Every filing
The company's filings with the SEC, newest first: 542 held. Insider, fund and large-holder filings have their own tables below.
| 30 Sep 2026 | 8-K | 28 Sep 2026 | 30 Sep, 4:20 PM ET | |
| 22 Sep 2026 | 8-K | 22 Sep 2026 | ||
| 18 Sep 2026 | 8-K | 17 Sep 2026 | ||
| 16 Sep 2026 | 8-K | 16 Sep 2026 | ||
| 18 Aug 2026 | 8-K | 14 Aug 2026 | ||
| 6 Aug 2026 | 10-Q | 30 Jun 2026 | ||
| 6 Aug 2026 | 8-K | 6 Aug 2026 | ||
| 2 Jul 2026 | 8-K | 30 Jun 2026 | ||
| 11 May 2026 | 10-Q | 31 Mar 2026 | ||
| 11 May 2026 | 8-K | 11 May 2026 | ||
| 7 May 2026 | 8-K | 5 May 2026 | ||
| 30 Apr 2026 | 8-K | 30 Apr 2026 | ||
| 24 Apr 2026 | 8-K | 22 Apr 2026 | ||
| 23 Mar 2026 | ARS | 31 Dec 2025 | ||
| 23 Mar 2026 | DEFA14A | – | ||
| 23 Mar 2026 | DEF 14A | 31 Dec 2025 | ||
| 12 Mar 2026 | 8-K | 12 Mar 2026 | ||
| 17 Feb 2026 | 10-K | 31 Dec 2025 | ||
| 17 Feb 2026 | 8-K | 17 Feb 2026 | ||
| 28 Jan 2026 | 8-K | 28 Jan 2026 | ||
| 9 Dec 2025 | 8-K | 4 Dec 2025 | ||
| 8 Dec 2025 | 8-K | 4 Dec 2025 | ||
| 24 Nov 2025 | 8-K | 18 Nov 2025 | ||
| 18 Nov 2025 | S-8 | – | ||
| 12 Nov 2025 | 8-K | 6 Nov 2025 | ||
| 7 Nov 2025 | 8-K | 6 Nov 2025 | ||
| 5 Nov 2025 | 8-K | 5 Nov 2025 | ||
| 3 Nov 2025 | 10-Q | 30 Sep 2025 | ||
| 3 Nov 2025 | 8-K | 3 Nov 2025 | ||
| 14 Oct 2025 | 8-K | 14 Oct 2025 | ||
| 6 Oct 2025 | 8-K | 1 Oct 2025 | ||
| 3 Oct 2025 | 8-K | 30 Sep 2025 | ||
| 1 Oct 2025 | 8-K | 30 Sep 2025 | ||
| 5 Aug 2025 | 10-Q | 30 Jun 2025 | ||
| 5 Aug 2025 | 8-K | 5 Aug 2025 | ||
| 6 May 2025 | 10-Q | 31 Mar 2025 | ||
| 6 May 2025 | 8-K | 6 May 2025 | ||
| 2 May 2025 | 8-K | 1 May 2025 | ||
| 21 Mar 2025 | 8-K | 17 Mar 2025 | ||
| 18 Mar 2025 | ARS | 31 Dec 2024 | ||
| 18 Mar 2025 | DEFA14A | – | ||
| 18 Mar 2025 | DEF 14A | 31 Dec 2024 | ||
| 18 Feb 2025 | 10-K | 31 Dec 2024 | ||
| 18 Feb 2025 | 8-K | 18 Feb 2025 | ||
| 13 Feb 2025 | 8-K | 11 Feb 2025 | ||
| 8 Jan 2025 | 8-K | 8 Jan 2025 | ||
| 31 Oct 2024 | 10-Q | 30 Sep 2024 | ||
| 31 Oct 2024 | 8-K | 31 Oct 2024 | ||
| 6 Aug 2024 | 10-Q | 30 Jun 2024 | ||
| 6 Aug 2024 | 8-K | 6 Aug 2024 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 4,810 | $108.18 | $520.3K | 782,970 | 8 Oct 2026 |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 3,090 | $108.91 | $336.5K | 779,880 | 8 Oct 2026 |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 11,900 | $110.00 | $1.3M | 767,980 | 8 Oct 2026 |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 200 | $110.51 | $22.1K | 767,780 | 8 Oct 2026 |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 8,600 | $111.03 | $954.9K | 779,180 | 8 Oct 2026 |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 10,300 | $111.84 | $1.2M | 768,880 | 8 Oct 2026 |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 900 | $112.78 | $101.5K | 767,980 | 8 Oct 2026 |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 200 | $113.69 | $22.7K | 767,780 | 8 Oct 2026 |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 2,300 | $107.90 | $248.2K | 785,480 | 8 Oct 2026 |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 6,000 | $109.33 | $656.0K | 779,480 | 8 Oct 2026 |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 9,920 | $109.89 | $1.1M | 769,560 | 8 Oct 2026 |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 1,780 | $110.81 | $197.2K | 767,780 | 8 Oct 2026 |
| 1 Oct 2026 | Posard Matthew L.Director | Sale under a trading plan | 730 | $107.17 | $78.2K | 58,109 | 2 Oct 2026 |
| 1 Oct 2026 | Posard Matthew L.Director | Sale under a trading plan | 3,300 | $108.45 | $357.9K | 54,809 | 2 Oct 2026 |
| 1 Oct 2026 | Posard Matthew L.Director | Sale under a trading plan | 1,100 | $109.57 | $120.5K | 53,709 | 2 Oct 2026 |
| 1 Oct 2026 | Posard Matthew L.Director | Sale under a trading plan | 100 | $110.04 | $11.0K | 53,609 | 2 Oct 2026 |
| 16 Sep 2026 | Posard Matthew L.Director | Sale under a trading plan | 3,100 | $106.13 | $329.0K | 74,735 | 17 Sep 2026 |
| 16 Sep 2026 | Posard Matthew L.Director | Sale under a trading plan | 3,000 | $106.83 | $320.5K | 71,735 | 17 Sep 2026 |
| 16 Sep 2026 | Posard Matthew L.Director | Sale under a trading plan | 8,896 | $108.04 | $961.1K | 62,839 | 17 Sep 2026 |
| 16 Sep 2026 | Posard Matthew L.Director | Sale under a trading plan | 4,000 | $108.99 | $436.0K | 58,839 | 17 Sep 2026 |
| 11 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 15,492 | $107.15 | $1.7M | 772,288 | 11 Sep 2026 |
| 11 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 4,508 | $107.55 | $484.8K | 767,780 | 11 Sep 2026 |
| 10 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 14,588 | $107.01 | $1.6M | 773,192 | 11 Sep 2026 |
| 10 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 5,412 | $107.58 | $582.2K | 767,780 | 11 Sep 2026 |
| 9 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 13,304 | $107.22 | $1.4M | 774,476 | 11 Sep 2026 |
| 9 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 6,596 | $107.82 | $711.2K | 767,880 | 11 Sep 2026 |
| 9 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 100 | $108.67 | $10.9K | 767,780 | 11 Sep 2026 |
| 19 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 7,200 | $106.36 | $765.8K | 780,580 | 19 Aug 2026 |
| 19 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 9,600 | $107.22 | $1.0M | 770,980 | 19 Aug 2026 |
| 19 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 3,200 | $107.77 | $344.8K | 767,780 | 19 Aug 2026 |
| 18 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 5,703 | $103.08 | $587.9K | 782,077 | 19 Aug 2026 |
| 18 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 4,897 | $104.11 | $509.8K | 777,180 | 19 Aug 2026 |
| 18 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 9,400 | $104.87 | $985.8K | 767,780 | 19 Aug 2026 |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 900 | $98.96 | $89.1K | 786,880 | 19 Aug 2026 |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 500 | $100.46 | $50.2K | 786,380 | 19 Aug 2026 |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 2,100 | $101.77 | $213.7K | 784,280 | 19 Aug 2026 |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 9,000 | $102.55 | $923.0K | 775,280 | 19 Aug 2026 |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 7,500 | $103.48 | $776.1K | 767,780 | 19 Aug 2026 |
| 10 Aug 2026 | Connaughton BernadetteDirector | Sale under a trading plan | 1,626 | $102.80 | $167.2K | 40,418 | 11 Aug 2026 |
| 8 Jul 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 888 | $79.28 | $70.4K | 768,815 | 9 Jul 2026 |
| 8 Jul 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 1,035 | $80.19 | $83.0K | 767,780 | 9 Jul 2026 |
| 1 Jul 2026 | Connaughton BernadetteDirector | Sale under a trading plan | 1,000 | $76.39 | $76.4K | 42,669 | 2 Jul 2026 |
| 1 Jul 2026 | Connaughton BernadetteDirector | Sale under a trading plan | 625 | $77.21 | $48.3K | 42,044 | 2 Jul 2026 |
| 29 Jun 2026 | Krishnan MaheshDirector | Sale under a trading plan | 7,304 | $75.00 | $547.8K | 14,462 | 30 Jun 2026 |
| 3 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 400 | $66.37 | $26.5K | 777,380 | 3 Jun 2026 |
| 3 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 1,500 | $67.67 | $101.5K | 775,880 | 3 Jun 2026 |
| 3 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 2,000 | $68.74 | $137.5K | 773,880 | 3 Jun 2026 |
| 3 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 6,100 | $69.69 | $425.1K | 767,780 | 3 Jun 2026 |
| 2 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 16,600 | $66.31 | $1.1M | 771,180 | 3 Jun 2026 |
| 2 Jun 2026 | Torley HelenPRESIDENT AND CEO | Sale under a trading plan | 3,400 | $66.75 | $226.9K | 767,780 | 3 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 16 Sep 2026 | MATTHEW POSARDDirector | 34,226 | $3.6M | 16 Sep 2026 |
| 17 Aug 2026 | Helen TorleyPresident, CEO, Director | 240,000 | $23.7M | 17 Aug 2026 |
| 11 Aug 2026 | CORTNEY A CAUDILLOfficer | 41,702 | $4.3M | 11 Aug 2026 |
| 10 Aug 2026 | BERNADETTE CONNAUGHTONDirector | 1,626 | $167.7K | 10 Aug 2026 |
| 29 Jun 2026 | MAHESH KRISHNANDirector | 7,304 | $547.5K | 29 Jun 2026 |
| 15 May 2026 | NICOLE LABROSSEFormer Officer | 14,700 | $986.6K | 15 May 2026 |
| 11 May 2026 | Helen TorleyPresident, CEO, Director | 101,923 | $6.5M | 11 May 2026 |
| 1 May 2026 | BERNADETTE CONNAUGHTONDirector | 4,875 | $310.3K | 1 May 2026 |
| 10 Mar 2026 | CORTNEY A CAUDILLOfficer | 8,857 | $599.1K | 10 Mar 2026 |
| 9 Mar 2026 | CORTNEY A CAUDILLOfficer | 20,000 | $1.4M | 9 Mar 2026 |
| 3 Feb 2026 | Helen TorleyPresident, CEO, Director | 150,000 | $11.2M | 3 Feb 2026 |
| 5 Jan 2026 | BERNADETTE CONNAUGHTONDirector | 2,000 | $140.6K | 5 Jan 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.21% | 6.2M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
| 29 Sep 2026 | Gilbert CisnerosCA31 | Sale (partial) | $1,001 - $15,000 | Self | 12 Oct 2026 |
| 9 Mar 2026 | Gilbert CisnerosCA31 | Purchase | $1,001 - $15,000 | Self | 7 Apr 2026 |
| 24 Mar 2025 | Gilbert CisnerosCA31 | Sale (partial) | $1,001 - $15,000 | Self | 7 Apr 2025 |
| 9 Sep 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 3 Oct 2024 |
| 12 Jul 2023 | Daniel GoldmanNY10 | Sale | $15,001 - $50,000 | Self | 13 Aug 2023 |
| 6 Dec 2022 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 13 Jan 2023 |
| 5 Aug 2022 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 16 Sep 2022 |
| 20 Aug 2021 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 20 Sep 2021 |
| 22 Oct 2020 | Gilbert CisnerosCA39 | Purchase | $1,001 - $15,000 | Self | 5 Nov 2020 |
| 19 Oct 2020 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 5 Nov 2020 |
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
| 30 Sep 2026 | 15.3M | +0.93% | 4.54 |
| 15 Sep 2026 | 15.2M | +1.84% | 11.59 |
| 31 Aug 2026 | 14.9M | +1.67% | 8.69 |
| 14 Aug 2026 | 14.6M | +4.38% | 5.01 |
| 31 Jul 2026 | 14.0M | +5.46% | 8.35 |
| 15 Jul 2026 | 13.3M | +0.53% | 7.27 |
| 30 Jun 2026 | 13.2M | +2.15% | 6.27 |
| 15 Jun 2026 | 12.9M | -5.1% | 7.84 |
| 29 May 2026 | 13.6M | +1.9% | 8.12 |
| 15 May 2026 | 13.4M | -6.9% | 6.72 |
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
743
quarter to 30 Jun 2026
Added or new
358
since 31 Mar 2026
Trimmed
205
in the quarter
Largest holder
BlackRock, Inc.
$1.0B
| BlackRock, Inc. | $1.0B | 13.3M | +6.0K | Held | 0.01% | Filing ↗ |
| Vanguard Capital Management LLC | $418.8M | 5.4M | +80.1K | Added | 0.01% | Filing ↗ |
| Vanguard Portfolio Management LLC | $414.8M | 5.3M | +49.8K | Added | 0.02% | Filing ↗ |
| State Street Corp. | $405.4M | 5.2M | +241.6K | Added | 0.01% | Filing ↗ |
| Invesco Ltd. | $248.7M | 3.2M | -834.5K | Trimmed | 0.02% | Filing ↗ |
| Morgan Stanley | $221.7M | 2.8M | +270.3K | Added | 0.01% | Filing ↗ |
| Boston Partners | $216.8M | 2.8M | +89.9K | Added | 0.19% | Filing ↗ |
| Bank of America Corp. | $214.5M | 2.7M | -172.5K | Trimmed | 0.01% | Filing ↗ |
| Geode Capital Management, LLC | $197.3M | 2.5M | +14.2K | Added | 0.01% | Filing ↗ |
| William Blair Investment Management, LLC | $196.5M | 2.5M | -14.9K | Trimmed | 0.59% | Filing ↗ |
| Snyder Capital Management L P | $187.5M | 2.4M | +73.0K | Added | 3.24% | Filing ↗ |
| Dimensional Fund Advisors LP | $163.5M | 2.1M | +9.7K | Added | 0.03% | Filing ↗ |
| D. E. Shaw & Co., Inc. | $157.0M | 2.0M | +137.8K | Added | 0.10% | Filing ↗ |
| Assenagon Asset Management S.A. | $156.2M | 2.0M | – | Held | 0.10% | Filing ↗ |
| Los Angeles Capital Management LLC | $151.7M | 1.9M | +1.2M | Added | 0.56% | Filing ↗ |
| Royal London Asset Management Ltd | $141.7M | 1.8M | +200.3K | Added | 0.26% | Filing ↗ |
| Arrowstreet Capital, Limited Partnership | $133.4M | 1.7M | -213.5K | Trimmed | 0.06% | Filing ↗ |
| Two Sigma Investments, LP | $129.4M | 1.7M | +68.3K | Added | 0.10% | Filing ↗ |
| UBS Group AG | $116.8M | 1.5M | +578.2K | Added | 0.02% | Filing ↗ |
| Fuller & Thaler Asset Management, Inc. | $116.7M | 1.5M | +25.7K | Added | 0.32% | Filing ↗ |
| Norges Bank | $116.1M | 1.5M | – | Held | 0.01% | Filing ↗ |
| First Trust Advisors LP | $110.9M | 1.4M | -65.3K | Trimmed | 0.07% | Filing ↗ |
| LSV Asset Management | $110.4M | 1.4M | +38.7K | Added | 0.20% | Filing ↗ |
| AllianceBernstein L.P. | $109.6M | 1.7M | -40.0K | Trimmed | 0.04% | Filing ↗ |
| Stephens Investment Management Group LLC | $109.0M | 1.4M | +174.2K | Added | 1.17% | Filing ↗ |
| Wells Fargo & Company | $108.8M | 1.4M | -145.3K | Trimmed | 0.02% | Filing ↗ |
| GW&K Investment Management, LLC | $106.0M | 1.4M | -40.0K | Trimmed | 0.83% | Filing ↗ |
| Jupiter Topco LLC | $105.6M | 1.3M | – | first | 0.04% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $103.5M | 1.3M | +33.1K | Added | 0.01% | Filing ↗ |
| Goldman Sachs Group Inc. | $99.4M | 1.3M | +540.2K | Added | 0.01% | Filing ↗ |
| Franklin Resources Inc. | $97.4M | 1.2M | +87.0K | Added | 0.02% | Filing ↗ |
| Congress Asset Management Co. | $96.2M | 1.2M | -51.5K | Trimmed | 0.59% | Filing ↗ |
| Nomura Asset Management International Inc. | $92.7M | 1.2M | -3.2K | Trimmed | 0.14% | Filing ↗ |
| TD Asset Management Inc | $87.3M | 1.1M | -52.9K | Trimmed | 0.08% | Filing ↗ |
| Epoch Investment Partners, Inc. | $86.0M | 1.1M | -39.8K | Trimmed | 0.49% | Filing ↗ |
| Northern Trust Corp. | $85.1M | 1.1M | -23.6K | Trimmed | 0.01% | Filing ↗ |
| Boston Trust Walden Corp | $84.8M | 1.1M | +403.5K | Added | 0.65% | Filing ↗ |
| Caisse de depot et placement du Quebec | $83.9M | 1.1M | -48.8K | Trimmed | 0.12% | Filing ↗ |
| Federated Hermes, Inc. | $75.3M | 962.0K | -161.2K | Trimmed | 0.11% | Filing ↗ |
| Bank of Montreal | $73.8M | 942.4K | -113.2K | Trimmed | 0.03% | Filing ↗ |
| Mizuho Markets Cayman LP | $65.3M | 834.5K | +834.5K | New | 2.45% | Filing ↗ |
| Bank of New York Mellon Corp | $62.8M | 802.2K | -181.6K | Trimmed | 0.01% | Filing ↗ |
| AQR Capital Management LLC | $61.5M | 785.6K | -230.9K | Trimmed | 0.02% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $59.9M | 765.7K | +18.3K | Added | 0.01% | Filing ↗ |
| Gotham Asset Management, LLC | $57.9M | 739.3K | -7.6K | Trimmed | 0.14% | Filing ↗ |
| Jane Street Group, LLC | $54.4M | 694.7K | -137.0K | Trimmed | 0.04% | Filing ↗ |
| Handelsbanken Fonder AB | $49.5M | 631.9K | +138.4K | Added | 0.14% | Filing ↗ |
| Sei Investments Co. | $43.1M | 551.1K | +93.3K | Added | 0.04% | Filing ↗ |
| Royal Bank of Canada | $42.7M | 545.8K | -112.5K | Trimmed | 0.01% | Filing ↗ |
| Kennedy Capital Management LLC | $42.7M | 545.0K | +60.4K | Added | 0.76% | Filing ↗ |
Executive pay and performance
What the chief executive and the other named officers were paid, as reported and as actually paid, next to the shareholder return and net income, from each proxy's pay-versus-performance table.
| Fiscal year | CEO pay, as reported | CEO pay, actually paid | Other officers, as reported (average) | Other officers, actually paid (average) | Shareholder return, $100 | Peer return, $100 | Net income | Proxy |
|---|---|---|---|---|---|---|---|---|
| FY ending 31 Dec 2025 | $23.2M | $39.7M | $3.6M | $4.9M | $158 | $125 | $316.9M | DEF 14A 23 Mar 2026 |
| FY ending 31 Dec 2024 | $12.7M | $20.7M | $4.2M | $6.3M | $112 | $93 | $444.1M | DEF 14A 23 Mar 2026 |
| FY ending 31 Dec 2023 | $11.8M | $-3.6M | $3.6M | $0.2M | $87 | $94 | $281.6M | DEF 14A 23 Mar 2026 |
| FY ending 31 Dec 2022 | $9.7M | $22.8M | $2.4M | $3.2M | $133 | $90 | $202.1M | DEF 14A 23 Mar 2026 |
| FY ending 31 Dec 2021 | $7.5M | $6.0M | $2.4M | $0.6M | $94 | $100 | $402.7M | DEF 14A 23 Mar 2026 |
| FY ending 31 Dec 2020 | $6.5M | $24.4M | $1.8M | $4.4M | $241 | $126 | $129.0M | DEF 14A 18 Mar 2025 |
Each year from the newest proxy that reports it. Pay actually paid follows the SEC's definition and can be below zero when share awards fall in value. n the proxy's net income differs from the 10-K or was tagged without its scale: hover for which.
Shareholder votes
The vote count on every proposal at each meeting, from the company's 8-K.
| Proposal | For | Against or withheld | Abstain | Broker non-votes | For, % of for and against | Result |
|---|---|---|---|---|---|---|
| Proposal 1: Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: | ||||||
| Bernadette Connaughton | 89,053,734 | 5,068,160 | 127,131 | 9,889,219 | 94.6% | – |
| Matthew L. Posard | 82,739,433 | 10,236,878 | 1,272,714 | 9,889,219 | 89.0% | – |
| Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: | ||||||
| All shares voting | 84,682,518 | 9,311,426 | 255,081 | 9,889,219 | 90.1% | – |
Counts as the company reports them in its 8-K. A result shows when the filing states one. Meetings since 2023.
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics, Inc.this company | $14.3B | $1.7B | 41.2% | 35.9% | 24.9% | 288.1% | 37.5× | 26.6× |
| Amgen Inc. | $237.5B | $38.1B | 9.1% | 30.0% | 23.0% | 74.8% | 27.3× | 19.9× |
| Gilead Sciences, Inc. | $193.7B | $30.5B | 5.5% | -8.2% | -10.6% | -27.4% | – | – |
| Moderna, Inc. | $79.8B | $2.2B | -27.6% | -149.0% | -141.4% | -46.6% | – | – |
| argenx SE | $54.0B | $4.2B | 89.9% | – | – | 17.6% | 44.6× | – |
| Biogen Inc. | $37.1B | $10.0B | 0.3% | 10.1% | 8.3% | 4.4% | 44.4× | 23.7× |
| BioNTech SE | $22.1B | $3.2B | 4.3% | -49.0% | -39.6% | -5.9% | – | – |
| Exelixis, Inc. | $16.1B | $2.4B | 9.2% | 39.9% | 35.3% | 46.7% | 20.3× | 15.8× |
| Neurocrine Biosciences Inc. | $14.5B | $3.4B | 34.4% | 23.6% | 20.9% | 19.1% | 20.9× | 16.8× |
| Bio-Techne Corp. | $11.3B | $1.2B | -0.4% | 20.7% | 15.0% | 8.6% | 63.1× | 32.2× |
| Repligen Corp. | $10.0B | $785.1M | 16.5% | 8.2% | 5.3% | 2.0% | 242.1× | 69.2× |
What the company does
Halozyme Therapeutics is a biopharmaceutical company that licenses its drug delivery technology to other drug makers and sells a few products of its own. Its ENHANZE technology uses rHuPH20, its patented recombinant human hyaluronidase enzyme, to let drugs that would otherwise be given intravenously, or in larger or more frequent shots, be injected under the skin. Its principal offices and research facilities are in San Diego, California.
How ENHANZE works
rHuPH20 temporarily breaks down hyaluronan, a carbohydrate in the tissue under the skin, so that large volumes of injected drugs such as monoclonal antibodies can spread and be absorbed faster. The enzyme acts locally, with a tissue half-life of less than 30 minutes, and the hyaluronan rebuilds to its normal density within two days. Partners use it to turn intravenous drugs into subcutaneous injections, to allow fixed-dose rather than weight-based dosing and to extend the time between doses.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence